We recently published our article 10 Best Cheap AI Medicine Stocks to Buy Now. In this piece, we take a closer look at Absci Corporation (NASDAQ:ABSI) to examine its latest developments, pipeline progress, and why it continues to draw attention from investors.
Artificial intelligence is no longer limited to chatbots, digital advertising and Silicon Valley experiments. It is moving into hospitals, laboratories and pharmaceutical research, where algorithms are helping scientists discover potential medicines, interpret medical images, analyze genetic information and identify treatments suited to individual patients.
Interestingly, the termx term “artificial intelligence” was introduced in 1956, but medical AI took decades to become commercially practical. Modern healthcare systems now generate enormous amounts of clinical, imaging and genomic data—the exact type of information machine-learning models are designed to analyze.
Why Medicine Could Be AI’s Next Major Market
Drug development has traditionally required years of research, costly clinical trials and thousands of unsuccessful experiments. AI drug discovery platforms cannot eliminate those risks, but they can help researchers screen molecules, predict biological interactions and prioritize the most promising candidates before expensive trials begin.
Medical imaging has also become one of the earliest real-world applications of artificial intelligence in healthcare. AI-powered diagnostics can assist doctors in detecting abnormalities, improving image quality and prioritizing urgent cases. Meanwhile, precision medicine platforms are using clinical and genomic data to help match patients with more appropriate treatments.
These developments have encouraged investors to search for the best AI healthcare stocks, AI biotech stocks and medical AI companies positioned to benefit from the industry’s long-term expansion.
A Low Share Price Does Not Always Mean Cheap
A stock trading below $10 may look affordable, but it can still be overvalued if the company generates little revenue, loses money and repeatedly issues new shares. On the other hand, a profitable healthcare technology company trading above $50 may be undervalued when its earnings, cash flow and competitive advantages support a higher valuation.
The most attractive cheap AI medicine stocks therefore combine genuine medical applications with reasonable valuations, sufficient cash reserves, improving financial performance and meaningful long-term growth opportunities.
Finding the Best AI Medicine Stocks
This ranking evaluates NYSE- and Nasdaq-listed companies based on their AI exposure, valuation, revenue growth, financial strength, clinical potential and competitive position. Higher-risk companies were penalized for heavy losses, shareholder dilution, limited cash runways and uncertain paths to profitability.
The countdown begins with the most speculative AI medicine stock at No. 10 and ends with the strongest overall risk-adjusted pick at No. 1. These companies operate across AI drug discovery, precision medicine, genomic analysis, medical imaging, digital health and clinical research—some of the most promising fields where artificial intelligence could reshape modern healthcare.
CHECK THIS OUT: Top 10 Healthcare Stocks to Buy With $1000 in 2026 and 10 Best Medicine Stocks That Could Make Investors 100% Richer.
Our Methodology
For the 10 Cheap AI Medicine Stocks That Could Make You a Millionaire, we ranked each company based on its valuation, medical AI exposure, revenue growth, financial strength, clinical potential and overall investment risk.
10 Best Cheap AI Medicine Stocks to Buy Now
9. Absci Corporation (NASDAQ:ABSI)
Absci Corporation (NASDAQ: ABSI) takes ninth place as a generative AI drug-discovery company attempting to design therapeutic proteins and antibodies more efficiently. At approximately $8.82 per share, the stock has significant upside if the platform produces successful medicines, although its roughly $1.4 billion market capitalization already reflects considerable optimism.
Traditional antibody development can involve screening enormous numbers of possible molecules before researchers find a viable candidate. The company aims to redesign that process by combining generative AI with synthetic biology and laboratory validation. Its platform can potentially create antibodies with specific biological properties rather than relying only on trial-and-error screening.
This is an ambitious use of artificial intelligence in healthcare. A successful platform could attract development partnerships from pharmaceutical companies looking to reduce research costs and improve the probability of discovering useful medicines. The company also maintains its own pipeline, giving shareholders potential exposure to future clinical and licensing milestones.
The financial picture improved after an underwritten stock offering completed in June 2026. Cash, cash equivalents and marketable securities reached $201.1 million at the end of the quarter, up from $125.7 million three months earlier. Management believes this capital can fund operations into the second half of 2028. The cash position and operating update were included in the latest quarterly report.
That longer runway provides time to generate clinical evidence, but the recent financing also illustrates an important biotechnology risk. When a company has little commercial revenue, research must usually be funded through partnerships or new share issuance. Existing shareholders can be diluted before a successful drug reaches the market.
The stock belongs among promising AI drug-discovery stocks, but it remains dependent on experimental results. Its platform could become highly valuable, yet investors are still paying for a possibility rather than an established stream of earnings.
YOU MUST READ THIS: Top 10 Healthcare Stocks to Buy With $1000 in 2026
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
